Parabilis Medicines charts $413M IPO to back peptide pipelinenews2026-06-04T13:04:21+00:00June 4th, 2026|Endpoints News|
Kardigan readies Nasdaq IPO to back three cardio drugsnews2026-05-27T00:15:45+00:00May 27th, 2026|Endpoints News|
Parabilis reveals IPO plans the day after Regeneron deal as listings heat upnews2026-05-20T10:40:54+00:00May 20th, 2026|Endpoints News|
Odyssey raises more than $300M as biotech goes public in IPOnews2026-05-08T01:44:43+00:00May 8th, 2026|Endpoints News|
Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutnews2026-05-01T11:34:58+00:00May 1st, 2026|Endpoints News|
Odyssey Therapeutics will try again to IPO, this time in a warmer marketnews2026-04-20T00:54:19+00:00April 20th, 2026|Endpoints News|
Kailera IPO interview: CEO Renaud talks biotech market, China and obesity pipelinenews2026-04-17T16:06:25+00:00April 17th, 2026|Endpoints News|
Kailera raises $625M IPO in biotech recordnews2026-04-17T11:28:56+00:00April 17th, 2026|Endpoints News|
Updated: Seaport and Hemab file for IPOs, as Kailera pricesnews2026-04-13T01:10:39+00:00April 13th, 2026|Endpoints News|
Pulmonary fibrosis biotech Avalyn Pharma files for IPOnews2026-04-09T01:20:45+00:00April 9th, 2026|Endpoints News|
